Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series

Postgraduate Medicine

Volumn 127, Issue 4, 2015, Pages 413-417

  Cornella, Scott L ^a   Stine, Jonathan G ^b   Kelly, Virginia ^b   Caldwell, Stephen H ^b   Shah, Neeral L ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Arthralgias; Chronic liver disease; Cirrhosis; Protease inhibitors; Vasculitis; Viral hepatitis

Indexed keywords

AMITRIPTYLINE; BOCEPREVIR; CORTICOSTEROID; CRYOGLOBULIN; GABAPENTIN; PEGINTERFERON; RHEUMATOID FACTOR; RIBAVIRIN; RITUXIMAB; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROPATHIC PAIN; RASH; URINALYSIS; ANALOGS AND DERIVATIVES; CASE REPORT; COMPLICATION; HEPATITIS C, CHRONIC; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; URIDINE MONOPHOSPHATE;

EID: 84937718271     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2015.1021660     Document Type: Article

References (24)

1. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-12.
2. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011;9:923-30.
3. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995;123:615-20.
4. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014;46:S165-73.
5. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000;79:47-56.
6. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291-300.
7. Gorevic PD, Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol 1991;28:79-94.
8. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multicentre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995;88:115-26.
9. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002;55:4-13.
10. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74.
11. Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10:444-54.
12. Sitole M, Silva M, Spooner L, et al. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther 2013;35:190-7.
13. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-79.e3.
14. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
15. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58:1918-29.
16. Saadoun D, Resche Rigon M, Pol S, et al. PegIFNalpha/ribavirin/ protease inhibitor combination in severe hepatitis C virusassociated mixed cryoglobulinemia vasculitis. J Hepatol 2015;62:24-30.
17. Kawakami T, Ooka S, Mizoguchi M, et al. Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir. Ann Intern Med 2008;149:911-12.
18. Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1. Ann Intern Med 1999;130:226-30.
19. Ferri C, Antonelli A, Mascia MT, et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007;7:114-20.
20. Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007;39:S13-21.
21. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002;36:978-85.
22. Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011;10:714-19.
23. Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46:2252-4. author reply 54-5.
24. Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev 2014;12: Cd010404.